Advanced

Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid

Ahlström-Emanuelsson, Cecilia LU ; Persson, Carl LU ; Svensson, Christer LU ; Andersson, Morgan LU ; Hosszu, Z; Akerlund, A and Greiff, Lennart LU (2002) In Annals of Allergy, Asthma & Immunology 89(2). p.159-165
Abstract
Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3... (More)
Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3 days' treatment, individualized nasal allergen-challenges were administered daily for 7 days while the treatment continued. Nasal symptoms and peak inspiratory flow (PIF) were recorded. Results: During the last 3 days of allergen challenge without active treatment, consistent around-the-clock symptoms were recorded and recordings during these days were used in the analysis. With few exceptions the active treatments reduced nasal symptoms and improved nasal PIF (P values <0.001 to 0.05). Budesonide caused dose-dependent improvements in evening symptoms, morning nasal PIF, and nasal PIF recorded 10 minutes after allergen-challenge (P values <0.05). Budesonide 256 mug produced greater improvement than mometasone furoate 200 mug for nasal PIF 10 minutes after allergen-challenge (P < 0.05). Conclusion: The present allergen challenge method, producing consistent symptoms and nasal PIF data, emerges as a model of seasonal allergic rhinitis well suited for exploring potency and efficacy of drug intervention. The present data do not support the view that mometasone furoate is a more potent antirhinitis drug than budesonide. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Allergy, Asthma & Immunology
volume
89
issue
2
pages
159 - 165
publisher
American College of Allergy, Asthma & Immunology
external identifiers
  • wos:000177545200011
  • pmid:12197572
  • scopus:0036706887
ISSN
1081-1206
language
English
LU publication?
yes
id
bf9d0465-e04b-401f-9b97-b6a196cf53c0 (old id 331133)
alternative location
http://openurl.ingenta.com/content?genre=article&issn=1081-1206&volume=89&issue=2&spage=159&epage=165
date added to LUP
2007-08-06 13:44:06
date last changed
2017-01-01 04:40:02
@article{bf9d0465-e04b-401f-9b97-b6a196cf53c0,
  abstract     = {Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3 days' treatment, individualized nasal allergen-challenges were administered daily for 7 days while the treatment continued. Nasal symptoms and peak inspiratory flow (PIF) were recorded. Results: During the last 3 days of allergen challenge without active treatment, consistent around-the-clock symptoms were recorded and recordings during these days were used in the analysis. With few exceptions the active treatments reduced nasal symptoms and improved nasal PIF (P values &lt;0.001 to 0.05). Budesonide caused dose-dependent improvements in evening symptoms, morning nasal PIF, and nasal PIF recorded 10 minutes after allergen-challenge (P values &lt;0.05). Budesonide 256 mug produced greater improvement than mometasone furoate 200 mug for nasal PIF 10 minutes after allergen-challenge (P &lt; 0.05). Conclusion: The present allergen challenge method, producing consistent symptoms and nasal PIF data, emerges as a model of seasonal allergic rhinitis well suited for exploring potency and efficacy of drug intervention. The present data do not support the view that mometasone furoate is a more potent antirhinitis drug than budesonide.},
  author       = {Ahlström-Emanuelsson, Cecilia and Persson, Carl and Svensson, Christer and Andersson, Morgan and Hosszu, Z and Akerlund, A and Greiff, Lennart},
  issn         = {1081-1206},
  language     = {eng},
  number       = {2},
  pages        = {159--165},
  publisher    = {American College of Allergy, Asthma & Immunology},
  series       = {Annals of Allergy, Asthma & Immunology},
  title        = {Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid},
  volume       = {89},
  year         = {2002},
}